دورية أكاديمية
Development and Validation of a Contrast-Enhanced US VI-RADS for Evaluating Muscle Invasion in Bladder Cancer.
| العنوان: | Development and Validation of a Contrast-Enhanced US VI-RADS for Evaluating Muscle Invasion in Bladder Cancer. |
|---|---|
| المؤلفون: | Han J; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Lin M; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Lin Q; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Guo R; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Liao Y; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Wu Z; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Ye Y; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Guo Z; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Yao K; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Li L; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China., Zhou J; From the Departments of Ultrasound (J.H., M.L., Q.L., R.G., Y.L., Z.G., L.L., J.Z.) and Urology (Z.W., Y.Y., K.Y.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng Rd East, Guangzhou 510060, People's Republic of China. |
| المصدر: | Radiology [Radiology] 2024 Sep; Vol. 312 (3), pp. e232815. |
| نوع المنشور: | Journal Article; Validation Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Radiological Society of North America Country of Publication: United States NLM ID: 0401260 Publication Model: Print Cited Medium: Internet ISSN: 1527-1315 (Electronic) Linking ISSN: 00338419 NLM ISO Abbreviation: Radiology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Easton, PA : Radiological Society of North America Original Publication: [Illinois?] : Radiological Society of North America, [1923]- |
| مواضيع طبية MeSH: | Urinary Bladder Neoplasms*/diagnostic imaging , Urinary Bladder Neoplasms*/pathology , Contrast Media* , Ultrasonography*/methods , Neoplasm Invasiveness*/diagnostic imaging, Humans ; Male ; Female ; Middle Aged ; Aged ; Prospective Studies ; Urinary Bladder/diagnostic imaging ; Urinary Bladder/pathology ; Reproducibility of Results |
| مستخلص: | Background Contrast-enhanced US (CEUS) can be used preoperatively for evaluating muscle invasion in bladder cancer, which is important for determining appropriate treatment. However, diagnostic criteria for assessing this at CEUS have not been standardized. Purpose To develop and validate a CEUS Vesical Imaging Reporting and Data System (VI-RADS) for evaluating muscle invasion in bladder cancer. Materials and Methods This single-center prospective study consecutively enrolled patients with suspected bladder cancer. Participants underwent transabdominal or intracavity CEUS between July 2021 and May 2023. Participants were divided into a training set and a validation set at a 2:1 ratio based on the chronologic order of enrollment. The training set was used to identify major imaging features to include in CEUS VI-RADS, and the likelihood of muscle invasion per category was determined using a pathologic reference standard. The optimal VI-RADS category cutoff for muscle invasion was determined with use of the maximum Youden index. The validation set was assessed by novice and expert readers and used to validate the diagnostic performance and interreader agreement of the developed system. Results Overall, 126 participants (median age, 64 years [IQR, 57-71 years]; 107 male) and 67 participants (median age, 64 years [IQR, 56-69 years]; 49 male) were included in the training and validation set, respectively. In the training set, the optimal CEUS VI-RADS category cutoff for muscle invasion was VI-RADS 4 or higher (Youden index, 0.77). In the validation set, CEUS VI-RADS achieved good performance for both novice and expert readers (area under the receiver operating characteristic curve, 0.80 [95% CI: 0.70, 0.90] vs 0.88 [95% CI: 0.80, 0.97]; P = .09). The interreader agreement regarding the evaluation of CEUS VI-RADS category was 0.77 (95% CI: 0.65, 0.85) for novice readers, 0.87 (95% CI: 0.79, 0.92) for expert readers, and 0.78 (95% CI: 0.70, 0.84) for all readers. Conclusion The developed CEUS VI-RADS showed good performance and interreader agreement for the assessment of muscle invasion in bladder cancer. Chinese Clinical Trial Registry no. ChiCTR2100049435 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Morrell in this issue. |
| المشرفين على المادة: | 0 (Contrast Media) |
| تواريخ الأحداث: | Date Created: 20240910 Date Completed: 20240910 Latest Revision: 20240910 |
| رمز التحديث: | 20240910 |
| DOI: | 10.1148/radiol.232815 |
| PMID: | 39254448 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-1315 |
|---|---|
| DOI: | 10.1148/radiol.232815 |